Search

Your search keyword '"Boghaert, Erwin R."' showing total 159 results
Start Over Author "Boghaert, Erwin R."
159 results on '"Boghaert, Erwin R."'

6. Supplementary Figure 1 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

7. Data from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Author

Phillips, Andrew C., primary, Boghaert, Erwin R., primary, Vaidya, Kedar S., primary, Mitten, Michael J., primary, Norvell, Suzanne, primary, Falls, Hugh D., primary, DeVries, Peter J., primary, Cheng, Dong, primary, Meulbroek, Jonathan A., primary, Buchanan, Fritz G., primary, McKay, Laura M., primary, Goodwin, Neal C., primary, and Reilly, Edward B., primary

Published
2023
Full Text
View/download PDF

8. Legends for Tables S1 to S3 and Figures S1 to S5 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

9. Data from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

10. Figure S1 from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

Author

Phillips, Andrew C., primary, Boghaert, Erwin R., primary, Vaidya, Kedar S., primary, Falls, Hugh D., primary, Mitten, Michael J., primary, DeVries, Peter J., primary, Benatuil, Lorenzo, primary, Hsieh, Chung-Ming, primary, Meulbroek, Jonathan A., primary, Panchal, Sanjay C., primary, Buchanan, Fritz G., primary, Durbin, Kenneth R., primary, Voorbach, Martin J., primary, Reuter, David R., primary, Mudd, Sarah R., primary, Loberg, Lise I., primary, Ralston, Sherry L., primary, Cao, Diana, primary, Gan, Hui K., primary, Scott, Andrew M., primary, and Reilly, Edward B., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 5 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 4 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 3 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

16. Data from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

Author

Phillips, Andrew C., primary, Boghaert, Erwin R., primary, Vaidya, Kedar S., primary, Falls, Hugh D., primary, Mitten, Michael J., primary, DeVries, Peter J., primary, Benatuil, Lorenzo, primary, Hsieh, Chung-Ming, primary, Meulbroek, Jonathan A., primary, Panchal, Sanjay C., primary, Buchanan, Fritz G., primary, Durbin, Kenneth R., primary, Voorbach, Martin J., primary, Reuter, David R., primary, Mudd, Sarah R., primary, Loberg, Lise I., primary, Ralston, Sherry L., primary, Cao, Diana, primary, Gan, Hui K., primary, Scott, Andrew M., primary, and Reilly, Edward B., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

Author

Anderson, Mark G., primary, Falls, Hugh D., primary, Mitten, Michael J., primary, Oleksijew, Anatol, primary, Vaidya, Kedar S., primary, Boghaert, Erwin R., primary, Gao, Wenqing, primary, Palma, Joann P., primary, Cao, Diana, primary, Chia, Puey-Ling, primary, John, Thomas, primary, Gan, Hui K., primary, Scott, Andrew M., primary, and Reilly, Edward B., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 1, Table 2; Supplementary Figure 1 from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Author

Phillips, Andrew C., primary, Boghaert, Erwin R., primary, Vaidya, Kedar S., primary, Mitten, Michael J., primary, Norvell, Suzanne, primary, Falls, Hugh D., primary, DeVries, Peter J., primary, Cheng, Dong, primary, Meulbroek, Jonathan A., primary, Buchanan, Fritz G., primary, McKay, Laura M., primary, Goodwin, Neal C., primary, and Reilly, Edward B., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 3 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., primary, Peale, Franklin, primary, Boghaert, Erwin R., primary, Belmont, Lisa D., primary, Tan, Nguyen, primary, Young, Amy, primary, Mitten, Michael, primary, Ingalla, Ellen, primary, Darbonne, Walter C., primary, Oleksijew, Anatol, primary, Tapang, Paul, primary, Yue, Peng, primary, Oeh, Jason, primary, Lee, Leslie, primary, Maiga, Sophie, primary, Fairbrother, Wayne J., primary, Amiot, Martine, primary, Souers, Andrew J., primary, and Sampath, Deepak, primary

Published
2023
Full Text
View/download PDF

23. Data from Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells

Author

Damelin, Marc, primary, Geles, Kenneth G., primary, Follettie, Maximillian T., primary, Yuan, Ping, primary, Baxter, Michelle, primary, Golas, Jonathon, primary, DiJoseph, John F., primary, Karnoub, Maha, primary, Huang, Shuguang, primary, Diesl, Veronica, primary, Behrens, Carmen, primary, Choe, Sung E., primary, Rios, Carol, primary, Gruzas, Janet, primary, Sridharan, Latha, primary, Dougher, Maureen, primary, Kunz, Arthur, primary, Hamann, Philip R., primary, Evans, Deborah, primary, Armellino, Douglas, primary, Khandke, Kiran, primary, Marquette, Kimberly, primary, Tchistiakova, Lioudmila, primary, Boghaert, Erwin R., primary, Abraham, Robert T., primary, Wistuba, Ignacio I., primary, and Zhou, Bin-Bing S., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figures 1-6, Tables 1-5, Methods from Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells

Author

Damelin, Marc, primary, Geles, Kenneth G., primary, Follettie, Maximillian T., primary, Yuan, Ping, primary, Baxter, Michelle, primary, Golas, Jonathon, primary, DiJoseph, John F., primary, Karnoub, Maha, primary, Huang, Shuguang, primary, Diesl, Veronica, primary, Behrens, Carmen, primary, Choe, Sung E., primary, Rios, Carol, primary, Gruzas, Janet, primary, Sridharan, Latha, primary, Dougher, Maureen, primary, Kunz, Arthur, primary, Hamann, Philip R., primary, Evans, Deborah, primary, Armellino, Douglas, primary, Khandke, Kiran, primary, Marquette, Kimberly, primary, Tchistiakova, Lioudmila, primary, Boghaert, Erwin R., primary, Abraham, Robert T., primary, Wistuba, Ignacio I., primary, and Zhou, Bin-Bing S., primary

Published
2023
Full Text
View/download PDF

27. Tackling the tumor microenvironment – how can complex tumor models in vitroaid oncology drug development?

Author

Cox, Megan C., Mendes, Rita, Halwachs, Kathleen N., Domenici, Giacomo, Brito, Catarina, and Boghaert, Erwin R.

Abstract

ABSTRACTIntroductionIdentifying effective cancer drugs remains an inefficient process. Drug efficacy in traditional preclinical cancer models translates poorly into therapy in the clinic. Implementation of preclinical models that incorporate the tumor microenvironment (TME) is needed to improve selection of active drugs prior to clinical trials.Areas coveredProgression of cancer results from the behavior of cancer cells in concert with the host’s histopathological background. Nonetheless, complex preclinical models with a relevant microenvironment have yet to become an integral part of drug development. This review discusses existing models and provides a synopsis of active areas of cancer drug development where implementation would be of value. Their contribution to finding therapeutics in immune oncology, angiogenesis, regulated cell death and targeting tumor fibroblasts as well as optimization of drug delivery, combination therapy, and biomarkers of efficacy is considered.Expert opinionComplex tumor models in vitro (CTMIVs) that mimic the organotypic architecture of neoplastic tumors have boosted research into TME influence on traditional cytoreductive chemotherapy as well as the detection of specific TME targets. Despite advances in technical prowess, CTMIVs can only address specific aspects of cancer pathophysiology.

Published
2023
Full Text
View/download PDF

28. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Author

Souers, Andrew J., Leverson, Joel D., Boghaert, Erwin R., Ackler, Scott L., Catron, Nathaniel D., Chen, Jun, Dayton, Brian D., Ding, Hong, Enschede, Sari H., Fairbrother, Wayne J., Huang, David C.S., Hymowitz, Sarah G., Jin, Sha, Khaw, Seong Lin, Kovar, Peter J., Lam, Lloyd T., Lee, Jackie, Maecker, Heather L., Marsh, Kennan C., Mason, Kylie D., Mitten, Michael J., Nimmer, Paul M., Oleksijew, Anatol, Park, Chang H., Park, Cheol-Min, Phillips, Darren C., Roberts, Andrew W., Sampath, Deepak, Seymour, John F., Smith, Morey L., Sullivan, Gerard M., Tahir, Stephen K., Tse, Chris, Wendt, Michael D., Xiao, Yu, Xue, John C., Zhang, Haichao, Humerickhouse, Rod A., Rosenberg, Saul H., and Elmore, Steven W.

Subjects
Physiological aspects, Health aspects, Blood platelets -- Physiological aspects -- Health aspects, B cells -- Physiological aspects -- Health aspects, Blood proteins -- Physiological aspects -- Health aspects, Antineoplastic agents -- Physiological aspects -- Health aspects, Antimitotic agents -- Physiological aspects -- Health aspects
Abstract

Apoptosis, or programmed cell death, is a conserved and regulated process that is the primary mechanism for the removal of aged, damaged and unnecessary cells. The ability to block apoptotic [...], Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 ([BCL-X.sub.L]), which has shown clinical efficacy in some BCL-2-dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by [BCL-X.sub.L] inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.

Published
2013
Full Text
View/download PDF

29. Patient-Derived Explants of Colorectal Cancer: Histopathological and Molecular Analysis of Long-Term Cultures

Author

da Mata, Sara, primary, Franchi-Mendes, Teresa, additional, Abreu, Sofia, additional, Filipe, Bruno, additional, Morgado, Sónia, additional, Mesquita, Marta, additional, Albuquerque, Cristina, additional, Fonseca, Ricardo, additional, Santo, Vítor E., additional, Boghaert, Erwin R., additional, Rosa, Isadora, additional, and Brito, Catarina, additional

Published
2021
Full Text
View/download PDF

33. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia

Author

Cojocari, Dan, primary, Smith, Brianna N., additional, Purkal, Julie J., additional, Arrate, Maria P., additional, Huska, Jason D., additional, Xiao, Yu, additional, Gorska, Agnieszka, additional, Hogdal, Leah J., additional, Ramsey, Haley E., additional, Boghaert, Erwin R., additional, Phillips, Darren C., additional, and Savona, Michael R., additional

Published
2021
Full Text
View/download PDF

34. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

Author

Anderson, Mark G., primary, Falls, Hugh D., additional, Mitten, Michael J., additional, Oleksijew, Anatol, additional, Vaidya, Kedar S., additional, Boghaert, Erwin R., additional, Gao, Wenqing, additional, Palma, Joann P., additional, Cao, Diana, additional, Chia, Puey-Ling, additional, John, Thomas, additional, Gan, Hui K., additional, Scott, Andrew M., additional, and Reilly, Edward B., additional

Published
2020
Full Text
View/download PDF

40. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor

Author

Wang, Le, primary, Doherty, George A., additional, Judd, Andrew S., additional, Tao, Zhi-Fu, additional, Hansen, T. Matthew, additional, Frey, Robin R., additional, Song, Xiaohong, additional, Bruncko, Milan, additional, Kunzer, Aaron R., additional, Wang, Xilu, additional, Wendt, Michael D., additional, Flygare, John A., additional, Catron, Nathaniel D., additional, Judge, Russell A., additional, Park, Chang H., additional, Shekhar, Shashank, additional, Phillips, Darren C., additional, Nimmer, Paul, additional, Smith, Morey L., additional, Tahir, Stephen K., additional, Xiao, Yu, additional, Xue, John, additional, Zhang, Haichao, additional, Le, Phuong N., additional, Mitten, Michael J., additional, Boghaert, Erwin R., additional, Gao, Wenqing, additional, Kovar, Peter, additional, Choo, Edna F., additional, Diaz, Dolores, additional, Fairbrother, Wayne J., additional, Elmore, Steven W., additional, Sampath, Deepak, additional, Leverson, Joel D., additional, and Souers, Andrew James, additional

Published
2020
Full Text
View/download PDF

41. Abstract 1048: Preservation of tumor architecture and heterogeneity in long-term cultures of patient-derived explants

Author

Abreu, Sofia, primary, Silva, Fernanda, additional, Mata, Sara da, additional, Mendes, Teresa F., additional, Teixeira, Marta, additional, Filipe, Bruno, additional, Morgado, Sónia, additional, Francisco, Inês, additional, Mesquita, Marta, additional, Albuquerque, Cristina, additional, Chaves, Paula, additional, Fonseca, Ricardo, additional, Serpa, Jacinta, additional, Rosa, Isadora, additional, Felix, Ana, additional, Boghaert, Erwin R., additional, Santo, Vítor E., additional, and Brito, Catarina, additional

Published
2018
Full Text
View/download PDF

42. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

Author

Phillips, Andrew C., primary, Boghaert, Erwin R., additional, Vaidya, Kedar S., additional, Falls, Hugh D., additional, Mitten, Michael J., additional, DeVries, Peter J., additional, Benatuil, Lorenzo, additional, Hsieh, Chung-Ming, additional, Meulbroek, Jonathan A., additional, Panchal, Sanjay C., additional, Buchanan, Fritz G., additional, Durbin, Kenneth R., additional, Voorbach, Martin J., additional, Reuter, David R., additional, Mudd, Sarah R., additional, Loberg, Lise I., additional, Ralston, Sherry L., additional, Cao, Diana, additional, Gan, Hui K., additional, Scott, Andrew M., additional, and Reilly, Edward B., additional

Published
2018
Full Text
View/download PDF

43. The Volume of Three-Dimensional Cultures of Cancer Cells In Vitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors

Author

Boghaert, Erwin R., primary, Lu, Xin, additional, Hessler, Paul E., additional, McGonigal, Thomas P., additional, Oleksijew, Anatol, additional, Mitten, Michael J., additional, Foster-Duke, Kelly, additional, Hickson, Jonathan A., additional, Santo, Vitor E., additional, Brito, Catarina, additional, Uziel, Tamar, additional, and Vaidya, Kedar S., additional

Published
2017
Full Text
View/download PDF

44. ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET–Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

Author

Wang, Jieyi, primary, Anderson, Mark G., additional, Oleksijew, Anatol, additional, Vaidya, Kedar S., additional, Boghaert, Erwin R., additional, Tucker, Lora, additional, Zhang, Qian, additional, Han, Edward K., additional, Palma, Joann P., additional, Naumovski, Louie, additional, and Reilly, Edward B., additional

Published
2017
Full Text
View/download PDF

45. A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor

Author

Vaidya, Kedar S., primary, Oleksijew, Anatol, additional, Tucker, Lora A., additional, Pappano, William N., additional, Anderson, Mark G., additional, Grinnell, Christine M., additional, Zhang, Qian, additional, Heighton, Sarah J., additional, Mitten, Michael J., additional, Mishra, Sasmita, additional, Palma, Joann P., additional, Wang, Jieyi, additional, Reilly, Edward B., additional, and Boghaert, Erwin R., additional

Published
2017
Full Text
View/download PDF

46. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Author

Punnoose, Elizabeth A., primary, Leverson, Joel D., additional, Peale, Franklin, additional, Boghaert, Erwin R., additional, Belmont, Lisa D., additional, Tan, Nguyen, additional, Young, Amy, additional, Mitten, Michael, additional, Ingalla, Ellen, additional, Darbonne, Walter C., additional, Oleksijew, Anatol, additional, Tapang, Paul, additional, Yue, Peng, additional, Oeh, Jason, additional, Lee, Leslie, additional, Maiga, Sophie, additional, Fairbrother, Wayne J., additional, Amiot, Martine, additional, Souers, Andrew J., additional, and Sampath, Deepak, additional

Published
2016
Full Text
View/download PDF

47. ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Author

Phillips, Andrew C., primary, Boghaert, Erwin R., additional, Vaidya, Kedar S., additional, Mitten, Michael J., additional, Norvell, Suzanne, additional, Falls, Hugh D., additional, DeVries, Peter J., additional, Cheng, Dong, additional, Meulbroek, Jonathan A., additional, Buchanan, Fritz G., additional, McKay, Laura M., additional, Goodwin, Neal C., additional, and Reilly, Edward B., additional

Published
2016
Full Text
View/download PDF

48. Clearance of systemic hematologic tumors by venetoclax (Abt‐199) and navitoclax

Author

Ackler, Scott, primary, Oleksijew, Anatol, additional, Chen, Jun, additional, Chyla, Brenda J., additional, Clarin, Jerry, additional, Foster, Kelly, additional, McGonigal, Thomas, additional, Mishra, Sasmita, additional, Schlessinger, Sally, additional, Smith, Morey L., additional, Tahir, Stephen K., additional, Leverson, Joel D., additional, Souers, Andrew J., additional, Boghaert, Erwin R., additional, and Hickson, Jonathan, additional

Published
2015
Full Text
View/download PDF

49. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Author

Leverson, Joel D., primary, Phillips, Darren C., additional, Mitten, Michael J., additional, Boghaert, Erwin R., additional, Diaz, Dolores, additional, Tahir, Stephen K., additional, Belmont, Lisa D., additional, Nimmer, Paul, additional, Xiao, Yu, additional, Ma, Xiaoju Max, additional, Lowes, Kym N., additional, Kovar, Peter, additional, Chen, Jun, additional, Jin, Sha, additional, Smith, Morey, additional, Xue, John, additional, Zhang, Haichao, additional, Oleksijew, Anatol, additional, Magoc, Terrance J., additional, Vaidya, Kedar S., additional, Albert, Daniel H., additional, Tarrant, Jacqueline M., additional, La, Nghi, additional, Wang, Le, additional, Tao, Zhi-Fu, additional, Wendt, Michael D., additional, Sampath, Deepak, additional, Rosenberg, Saul H., additional, Tse, Chris, additional, S. Huang, David C., additional, Fairbrother, Wayne J., additional, Elmore, Steven W., additional, and Souers, Andrew J., additional

Published
2015
Full Text
View/download PDF

50. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

Author

Tao, Zhi-Fu, primary, Hasvold, Lisa, additional, Wang, Le, additional, Wang, Xilu, additional, Petros, Andrew M., additional, Park, Chang H., additional, Boghaert, Erwin R., additional, Catron, Nathaniel D., additional, Chen, Jun, additional, Colman, Peter M., additional, Czabotar, Peter E., additional, Deshayes, Kurt, additional, Fairbrother, Wayne J., additional, Flygare, John A., additional, Hymowitz, Sarah G., additional, Jin, Sha, additional, Judge, Russell A., additional, Koehler, Michael F. T., additional, Kovar, Peter J., additional, Lessene, Guillaume, additional, Mitten, Michael J., additional, Ndubaku, Chudi O., additional, Nimmer, Paul, additional, Purkey, Hans E., additional, Oleksijew, Anatol, additional, Phillips, Darren C., additional, Sleebs, Brad E., additional, Smith, Brian J., additional, Smith, Morey L., additional, Tahir, Stephen K., additional, Watson, Keith G., additional, Xiao, Yu, additional, Xue, John, additional, Zhang, Haichao, additional, Zobel, Kerry, additional, Rosenberg, Saul H., additional, Tse, Chris, additional, Leverson, Joel D., additional, Elmore, Steven W., additional, and Souers, Andrew J., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results